关闭

关闭

关闭

封号提示

内容

首页 FDA资料汇编FDA批准的抗肿瘤药物1949-2003

FDA资料汇编FDA批准的抗肿瘤药物1949-2003.doc

FDA资料汇编FDA批准的抗肿瘤药物1949-2003

longyun918
2018-09-07 0人阅读 0 0 0 暂无简介 举报

简介:本文档为《FDA资料汇编FDA批准的抗肿瘤药物1949-2003doc》,可适用于医药卫生领域

DrugNameTradeNameIndictionsManufacturerTimechlorambucilLeukeranChronicLymphocyticLeukemiapalliativetherapyGlaxoSmithKline meclorethamine,nitrogenmustardMustargen MerckMarleucovorinWellcovorin,LeucovorinLeucovorincalciumisindicatedfrouseincombinationwithfluorouraciltoprolongsurvivalinthepalliativetreatmentofpatientswithadvancedcolorectalcancerImmunexCorporationJunmercaptopurine,MPPurinethol GlaxoSmithKlineSepmethotrexateMethotrexate LederleLaboratoriesDecbusulfanoralMyleranChronicMyelogenousLeukemiapalliativetherapyGlaxoSmithKlineJunchlorambucilLeukeran GlaxoSmithKlineMarthiotepaThioplex ImmunexCorporationMarmethotrexateMethotrexate LederleLaboratoriesAugnandrolonephenpropionateDurabolin OrganonOctcyclophosphamideCytoxan,Neosar BristolMyersSquibbNovcyclophosphamideCytoxanInjection BristolMyersSquibbNovDROMOSTANOLONEPROPIONATEDROMOSTANOLONE EliLillyOctfluorouracil,FUAdrucilprolongsurvivalincombinationwithleucovorinICNPuertoRicoAprUracilMustardUracilMustardCapsules RobertsLabsSepvincristinpostmenopausalwomenwithdiseaseprogressionfollowingtamoxifentherapyAstraZenecaPharmaceuticalsDecporfimersodiumPhotofrinForuseinphotodynamictherapy(PDT)forpalliationofpatientswithcompletelyobstructingesophagealcancer,orpatientswithpartiallyobstructingesophagealcancerwhocannotbesatisfactorilytreatedwithNDYAGlasertherapyQLTPhototherapeuticsIncDecbleomycinBlenoxaneSclerosingagentforthetreatmentofmalignantpleuraleffusion(MPE)andpreventionofrecurrentpleuraleffusionsBristolMyersSquibbFebamifostineEthyolAccelApprov(clinicalbenefitnotestablished)ReductionofplatinumtoxicityinnonsmallcelllungcancerUSBioscienceMardaunorubicinliposomalDanuoXomeFirstlinecytotoxictherapyforadvanced,HIVrelatedKaposi'ssarcomaNexstar,IncAprdocetaxelTaxotereAccelApprov(clinicalbenefitsubsequentlyestablished)TreatmentofpatientswithlocallyadvancedormetastaticbreastcancerwhohaveprogressedduringanthracyclinebasedtherapyorhaverelapsedduringanthracyclinebasedadjuvanttherapyAventisPharmaceuticalMaygemcitabineGemzarTreatmentofpatientswithlocallyadvanced(nonresectablestageIIorIII)ormetastatic(stageIV)adenocarcinomaofthepancreasIndicatedforfirstlinetreatmentandforpatientspreviouslytreatedwithafluorouracilcontainingregimenEliLillyMayallopurinolZyloprimPatientswithleukemia,lymphomaandsolidtumormalignancieswhoarereceivingcancertherapywhichcauseselevationsofserumandurinaryuricacidlevelsandwhocannottolerateoraltherapyGlaxoSmithKlineMayetoposidephosphateEtopophosManagementofrefractorytesticulartumors,incombinationwithotherapprovedchemotherapeuticagentsBristolMyersSquibbMayetoposidephosphateEtopophosManagementofsmallcelllungcancer,firstline,incombinationwithotherapprovedchemotherapeuticagentsBristolMyersSquibbMaytopotecanHycamtinTreatmentofpatientswithmetastaticcarcinomaoftheovaryafterfailureofinitialorsubsequentchemotherapyGlaxoSmithKlineMayirinotecanCamptosarAccelApprov(clinicalbenefitsubsequentlyestablished)TreatmentofpatientswithmetastaticcarcinomaofthecolonorrectumwhosediseasehasrecurredorprogressedfollowingFUbasedtherapyPharmaciaUpjohnCompanyJunNofetumomabVerluma BoehringerIngelheimPharmaKG(formerlyDrKarlThomaeGmbH)AugcarmustinewithPolifeprosanImplantGliadelWaferForuseinadditiontosurgerytoprolongsurvivalinpatientswithrecurrentglioblastomamultiformewhoqualifyforsurgeryGuilfordPharmaceuticalsIncSepElliott'sBSolutionElliott'sBSolutionDiluentfortheintrathecaladministrationofmethotrexatesodiumandcytarabineforthepreventionortreatmentofmeningealleukemiaorlymphocyticlymphomaOrphanMedical,IncSepInterferonalfaaRoferonA HoffmannLaRocheIncNovSargramostimProkine ImmunexCorpNovmitoxantroneNovantroneForuseincombinationwithcorticosteroidsasinitialchemotherapyforthetreatmentofpatientswithpainrelatedtoadvancedhormonerefractoryprostatecancerImmunexCorporationNovidarubicinIdamycinIncombinationwithotherapprovedantileukemicdrugsforthetreatmentofacutenonlymphocyticleukemiainadultsPharmaciaUpjohnCompanyFebtoremifeneFarestonTreatmentofadvancedbreastcancerinpostmenopausalwomenOrionCorpMayletrozoleFemaraTreatmentofadvancedbreastcancerinpostmenopausalwomenNovartisJulpaclitaxelTaxolsecondlinetherapyforAIDSrelatedKaposi'ssarcomaBristolMyersSquibbAugInterferonalfabIntronAInterferonalfab,recombinantforinjectionisindicatedasadjuvanttosurgicaltreatmentinpatientsyearsofageorolderwithmalignantmelanomawhoarefreeofdiseasebutathighriskforsystemicrecurrencewithindaysofsurgeryScheringCorpNovInterferonalfabIntronAInterferonalfab,recombinantforInjectionisindicatedfortheinitialtreatmentofclinicallyaggressivefollicularNonHodgkin抯LymphomainconjunctionwithanthracyclinecontainingcombinationchemotherapyinpatientsyearsofageorolderScheringCorpNovInterferonalfabIntronAInterferonalfab,recombinantforInjectionisindicatedforintralesionaltreatmentofselectedpatientsyearsofageorolderwithcondylomataacuminatainvolvingexternalsurfacesofthegenitalandperianalareasScheringCorpNovInterferonalfabIntronAInterferonalfab,recombinantforInjectionisindicatedforthetreatmentofchronichepatitisCinpatientsyearsofageorolderwithcompensatedliverdiseasewhohaveahistoryofbloodorbloodproductexposureandorareHCVantibodypositiveScheringCorpNovInterferonalfabIntronAInterferonalfab,recombinantforInjectionisindicatedforthetreatmentofchronichepatitisBinpatientsyearsofageorolderwithcompensatedliverdiseaseandHBVreplicationScheringCorpNovInterferonalfabIntronAInterferonalfab,recombinantforInjectionisindicatedforthetreatmentofpatientsyearsofageorolderwithhairycellleukemiaScheringCorpNovInterferonalfabIntronAInterferonalfab,recombinantforInjectionisindicatedforthetreatmentofselectedpatientsyearsofageorolderwithAIDSRelatedKaposi'sSarcomaThelikelihoodofresponsetoINTRONAtherapyisgreaterinpatientswhoarewithoutsystemicsymptoms,whohavelimitedlymphadenopathyandwhohavearelativelyintactimmunesystemasindicatedbytotalCDcountScheringCorpNovOprelvekinNeumega GeneticsInstitute,IncNovRituximabRituxan Genentech,IncNovpaclitaxelPaxenetreatmentofadvancedAIDSrelatedKaposi'ssarcomaafterfailureoffirstlineorsubsequentsystemicchemotherapyBakerNortonPharmaceuticals,IncDectalcSclerosolForthepreventionoftherecurrenceofmalignantpleuraleffusioninsymptomaticpatientsBryanDecporfimersodiumPhotofrinForuseinphotodynamictherapyfortreatmentofmicroinvasiveendobronchialnonsmallcelllungcancerinpatientsforwhomsurgeryandradiotherapyarenotindicatedQLTPhototherapeuticsIncJandaunorubicin,daunomycinDaunorubicinLeukemiamyelogenousmonocyticerythroidofadultsremissioninductioninacutelymphocyticleukemiaofchildrenandadultsBedfordLabsJanhydroxyureaHydreaDecreaseneedfortransfusionsinsicklecellanemiaBristolMyersSquibbFebetoposidephosphateEtopophosManagementofrefractorytesticulartumorsandsmallcelllungcancerBristolMyersSquibbFebFilgrastimNeupogenNEUPOGENisindicatedtodecreasetheincidenceofinfectionasmanifestedbyfebrileneutropeniainpatientswithnonmyeloidmalignanciesreceivingmyelosuppressiveanticancerdrugsassociatedwithasignificantincidenceofsevereneutropeniawithfeverAmgen,IncAprFilgrastimNeupogenNEUPOGENisindicatedforreducingthetimetoneutrophilrecoveryandthedurationoffever,followinginductionorconsolidationhemotherapytreatmentofadultswithAMLAmgen,IncAprFilgrastimNeupogenNEUPOGENisindicatedtoreducethedurationofneutropeniaandneutropeniarelatedclinicalsequelae,eg,febrileneutropenia,inpatientswithnonmyeloidmalignanciesundergoingmyeloablativechemotherapyfollowedbymarrowtransplantationAmgen,IncAprpaclitaxelTaxolForfirstlinetherapyforthetreatmentofadvancedcarcinomaoftheovaryincombinationwithcisplatinBristolMyersSquibbAprcapecitabineXelodaAccelApprov(clinicalbenefitsubsequentlyestablished)Treatmentofmetastaticbreastcancerresistanttobothpaclitaxelandananthracyclinecontainingchemotherapyregimenorresistanttopaclitaxelandforwhomfurtheranthracyclinetherapymaybecontraindicated,eg,patientswhohavereceivedcumulativedosesofmgmofdoxorubicinordoxorubicinequivalentsRocheAprdocetaxelTaxotereForthetreatmentoflocallyadvancedormetastaticbreastcancerwhichhasprogressedduringanthracyclinebasedtreatmentorrelapsedduringanthracyclinebasedadjuvanttherapyAventisPharmaceuticalJunpaclitaxelTaxolforuseincombinationwithcisplatin,forthefirstlinetreatmentofnonsmallcelllungcancerinpatientswhoarenotcandidatesforpotentiallycurativesurgeryandorradiationtherapyBristolMyersSquibbJunBCGLiveTICEBCG OrganonTeknikaCorpAuggemcitabineGemzarForuseincombinationwithcisplatinforthefirstlinetreatmentofpatientswithinoperable,locallyadvanced(StageIIIAorIIIB)ormetastatic(StageIV)nonsmallcelllungcancerEliLillyAugpamidronateArediaTreatmentofosteolyticbonemetastasesofbreastcancerinconjunctionwithstandardantineoplastictherapyNovartisSepTrastuzumabHerceptinHERCEPTINasasingleagentisindicatedforthetreatmentofpatientswithmetastaticbreastcancerwhosetumorsoverexpresstheHERproteinandwhohavereceivedoneormorechemotherapyregimensfortheirmetastaticdiseaseGenentech,IncSepvalrubicinValstarForintravesicaltherapyofBCGrefractorycarcinomainsitu(CIS)oftheurinarybladderinpatientsforwhomimmediatecystectomywouldbeassociatedwithunacceptablemorbidityormortalityAnthra>MedevaSepirinotecanCamptosarFollowupoftreatmentofmetastaticcarcinomaofthecolonorrectumwhosediseasehasrecurredorprogressedfollowingFUbasedtherapyPharmaciaUpjohnCompanyOcttamoxifenNolvadextoreducetheincidenceofbreastcancerinwomenathighriskforbreastcancerAstraZenecaPharmaceuticalsOcttopotecanHycamtinTreatmentofsmallcelllungcancersensitivediseaseafterfailureoffirstlinechemotherapyInclinicalstudiessubmittedtosupportapproval,sensitivediseasewasdefinedasdiseaserespondingtochemotherapybutsubsequentlyprogressingatleastdays(inthephasestudy)oratleastdays(inthephasestudies)afterchemotherapyGlaxoSmithKlineNovporfimersodiumPhotofrinForuseinphotodynamictherapy(PDT)forreductionofobstructionandpalliationofsymptomsinpatientswithcompletelyorpartiallyobstructingendobroncialnonsmallcelllungcancer(NSCLC)QLTPhototherapeuticsIncDecalitretinoinPanretinTopicaltreatmentofcutaneouslesionsinpatientswithAIDSrelatedKaposi'ssarcomaLigandPharmaceuticalsFebbusulfanintravenousBusulfexUseincombinationwithcyclophoshamideasconditioningregimenpriortoallogeneichematopoieticprogenitorcelltransplantationforchronicmyelogenousleukemiaOrphanMedical,IncFebDenileukindiftitoxOntakAccelApprov(clinicalbenefitnotestablished)treatmentofpatientswithpersistentorrecurrentcutaneousTcelllymphomawhosemalignantcellsexpresstheCDcomponentoftheILreceptorSeragen,IncFebmethoxsalenUvadexFortheuseofUVADEXwiththeUVARPhotopheresisSysteminthepalliativetreatmentoftheskinmanifestationsofcutaneousTcelllymphoma(CTCL)thatisunresponsivetootherformsoftreatmentTherakosFebcytarabineliposomalDepoCytAccelApprov(clinicalbenefitnotestablished)IntrathecaltherapyoflymphomatousmeningitisSkyePharmaceuticalsApramifostineEthyolToreducepostradiationxerostomiaforheadandneckcancerwheretheradiationportincludesasubstantialportionoftheparotidglandsUSBioscienceJundoxorubicinliposomalDoxilAccelApprov(clinicalbenefitnotestablished)TreatmentofmetastaticcarcinomaoftheovaryinpatientwithdiseasethatisrefractorytobothpaclitaxelandplatinumbasedregimensSequusPharmaceuticals,IncJunEpoetinalfaepogenEPOGENBisindicatedforthereatmentofanemiarelatedtotherapywithzidovudineinHIVinfectedpatientsEPOGENBisindicatedtoelevateormaintaintheredbloodcelllevel(asmanifestedbythehematocritorhemoglobindeterminations)andtodecreasetheneedfortransfusionsinthesepatientsEPOGENDisnotindicatedforthetreatmentofanemiainHIVinfectedpatientsduetootherfactorssuchasironorfolatedeficiencies,hemolysisorgastrointestinalbleeding,whichshouldbemanagedappropriatelyAmgen,IncJulEpoetinalfaepogenEPOGENBisindicatedforthetreatmentofanemicpatients(hemoglobin>to<gdL)scheduledtoundergoelective,noncardiac,nonvascularsurgerytoreducetheneedforallogeneicbloodtransfusionsAmgen,IncJulEpoetinalfaepogenEPOGENBisindicatedforthetreatmentofanemiainpatientswithnonmyeloidmalignancieswhereanemiaisduetotheeffectofconcomitantlyadministeredchemotherapyEPOGENDisindicatedtodecreasetheneedfortransfusionsinpatientswhowillbereceivingconcomitantchemotherapyforaminimumofmonthsEPOGENBisnotindicatedforthetreatmentofanemiaincancerpatientsduetootherfactorssuchasironorfolatedeficiencies,hemolysisorgastrointestinalbleeding,whichshouldbemanagedappropriatelyAmgen,IncJulEpoetinalfaepogenEPOGENisindicatedforthetreatmentofanemiaassociatedwithCRF,includingpatientsondialysis(ESRD)andpatientsnotondialysisAmgen,InchJultemozolomideTemodarAccelApprov(clinicalbenefitnotestablished)Treatmentofadultpatientswithrefractoryanaplasticastrocytoma,ie,patientsatfirstrelapsewithdiseaseprogressiononanitrosoureaandprocarbazinecontainingregimenScheringAugepirubicinEllenceAcomponentofadjuvanttherapyinpatientswithevidenceofaxillarynodetumorinvolvementfollowingresectionofprimarybreastcancerPharmaciaUpjohnCompanySepexemestaneAromasinTreatmentofadvancebreastcancerinpostmenopausalwomenwhosediseasehasprogressedfollowingtamoxifentherapyPharmaciaUpjohnCompanyOctpaclitaxelTaxolFortheadjuvanttreatmentofnodepositivebreastcanceradministeredsequentiallytostandarddoxorubicincontainingcombinationtherapyBristolMyersSquibbOctcelecoxibCelebrexAccelApprov(clinicalbenefitnotestablished)ReductionofpolypnumberinpatientswiththeraregeneticdisorderoffamilialadenomatouspolyposisSearleDecdocetaxelTaxotereForlocallyadvancedormetastaticnonsmallcelllungcancerafterfailureofpriorplatinumbasedchemotherapyAventisPharmaceuticalDecbexarotenecapsulesTargretinForthetreatmentbyoralcapsuleofcutaneousmanifestationsofcutaneousTcelllymphomainpatientswhoarerefractorytoatleastonepriorsystemictherapyLigandPharmaceuticalsDecTrastuzumabHerceptinHerceptinincombinationwithpaclitaxelisindicatedfortreatmentofpatientswithmetastaticbreastcancerwhosetumorsoverexpresstheHERproteinandhadnotreceivedchemotherapyfortheirmetastaticdiseaseGenentech,IncFebirinotecanCamptosarForfirstlinetreatmentncombinationwithFUleucovorinofmetastaticcarcinomaofthecolonorrectumPharmaciaUpjohnCompanyAprgemtuzumabozogamicinMylotargAccelApprov(clinicalbenefitnotestablished)TreatmentofCDpositiveacutemyeloidleukemiainpatientsinfirstrelapsewhoareyearsofageorolderandwhoarenotconsideredcandidatesforcytotoxicchemotherapyWyethAyerstMaypaclitaxelTaxolFirstlineovariancancerwithhourinfusionBristolMyersSquibbJunbexarotenegelTargretinForthetopicaltreatmentofcutaneousmanifestationsofcutaneousTcelllymphomainpatientswhoarerefractorytoatleastonepriorsystemictherapyLigandPharmaceuticalsJuntamoxifenNolvadexInwomenwithDCIS,followingbreastsurgeryandradiation,NolvadexisindicatedtoreducetheriskofinvasivebreastcancerAstraZenecaPharmaceuticalsJunanastrozoleArimidexForfirstlinetreatmentofpostmenopausalwomenwithhormonereceptorpositiveorhormonereceptorunknownlocallyadvancedormetastaticbreastcancerAstraZenecaPharmaceuticalsSeparsenictrioxideTrisenoxSecondlinetreatmentofrelapsedorrefractoryAPLfollowingATRAplusananthracyclineCellTherapeuticSepletrozoleFemaraFirstlinetreatmentofpostmenopausalwomenwithhormonereceptorpositiveorhormonereceptorunknownlocallyadvancedormetastaticbreastcancerNovartisJancapecitabineXelodaInitialtherapyofpatientswithmetastaticcolorectalcarcinomawhentreatmentwithfluoropyrimidinetherapyaloneispreferredCombinationchemotherapyhasshownasurvivalbenefitcomparedtoFULValoneAsurvivalbenefitoverFULVhasnotbeendemonstratedwithXelodamonotherapyRocheAprAlemtuzumabCampathAccelApprov(clinicalbenefitnotestablished)CampathisindicatedforthetreatmentofBcellchroniclymphocyticleukemia(BCLL)inpatientswhohavebeentreatedwithalkylatingagentsandwhohavefailedfludarabinetherapyMillenniumandILEXPartners,LPMayimatinibmesylateGleevecAccelApprov(clinicalbenefitnotestablished)InitialtherapyofchronicmyelogenousleukemiaNovartisMaycapecitabineXelodaTreatmentincombinationwithdocetaxelofpatientswithmetastaticbreastcancerafterfailureofprioranthracyclinecontainingchemotherapyRocheSepDarbepoetinalfaAranespTreatmentofanemiaassociatedwithchronicrenalfailureAmgen,IncSepTrastuzumabHerceptin Genentech,IncDecPegfilgrastimNeulastaNeulastaisindicatedtodecreasetheincidenceofinfection,asmanifestedbyfebrileneutropenia,inpatientswithnonmyeloidmalignanciesreceivingmyelosuppressiveanticancerdrugsassociatedwithaclinicallysignificantincidenceoffebrileneutropeniaAmgen,IncJanimatinibmesylateGleevecAccelApprov(clinicalbenefitnotestablished)metastaticorunresectablemalignantgastrointestinalstromaltumorsNovartisFebIbritumomabTiuxetanZevalinAccelApprov(clinicalbenefitnotestablished)treatmentofpatientswithrelapsedorrefractorylowgrade,follicular,ortransformedBcellnonHodgkin'slymphoma,includingpatientswithRituximabrefractoryfollicularnonHodgkin抯lymphomaIDECPharmaceuticalsCorpFebzoledronateZometathetreatmentofpatientswithmultiplemyelomaandpatientswithdocumentedbonemetastasesfromsolidtumors,inconjunctionwithstandardantineoplastictherapyProstatecancershouldhaveprogressedaftertreatmentwithatleastonehormonaltherapyNovartisFebfulvestrantFaslodexthetreatmentofhormonereceptorpositivemetastaticbreastcancerinpostmenopausalwomenwithdiseaseprogressionfollowingantiestrogentherapyIPRAprInterferonalfabIntronA ScheringCorpJunInterferonalfabIntronAIntronA ScheringCorpJunInterferonalfabIntronA ScheringCorpJunRasburicaseElitekELITEKisindicatedfortheinitialmanagementofplasmauricacidlevelsinpediatricpatientswithleukemia,lymphoma,andsolidtumormalignancieswhoarereceivinganticancertherapyexpectedtoresultintumorlysisandsubsequentelevationofplasmauricacidSanofiSynthelabo,IncJulDarbepoetinalfaAranespAranespisindicatedforthetreatmentofanemiainpatientswithnonmyeloidmalignancieswhereanemiaisduetotheeffectofconcomitantlyadministeredchemotherapyAmgen,IncJulAsparaginaseElsparELSPARisindicatedinthetherapyofpatientswithacutelymphocyticleukemiaThisagentisusefulprimarilyincombinationwithotherchemotherapeuticagentsintheinductionofremissionsofthediseaseinpediatricpatientsMerckCo,IncAugoxaliplatinEloxatinAccelApprov(clinicalbenefitnotestablished)incombinationwithinfusionalFULV,isindicatedforthetreatmentofpatientswithmetastaticcarcinomaofthecolonorrectumwhosediseasehasrecurredorprogressedduringorwithinmonthsofcompletionoffirstlinetherapywiththecombinationofbolusFULVandirinotecanSanofiSynthelaboAugTrastuzumabHerceptin Genentech,IncAugTrastuzumabHerceptin Genentech,IncAuganastrozoleArimidexAccelApprov(clinicalbenefitnotestablished)fortheadjuvanttreatmentofpostmenopausalwomenwithhormonereceptorpositiveearlybreastcancerAstraZenecaSepOprelvekinNeumega GeneticsInstitute,IncSepOprelvekinNeumegaNeumegaisindicatedforthepreventionofseverethrombocytopeniaandthereductionoftheneedforplatelettransfusionsfollowingmyelosuppressivechemotherapyinadultpatientswithnonmyeloidmalignancieswhoareathighriskofseverethrombocytopeniaGeneticsInstitute,IncSepdexrazoxaneZinecardreducingtheincidenceandseverityofcardiomyopathyassociatedwithdoxorubicinadministrationinwomenwithmetastaticbreastcancerwhohavereceivedacumulativedoxorubicindoseofmgmandwhowillcontinuetoreceivedoxorubicintherapytomaintaintumorcontrolItisnotrecommendedforusewiththeinitiationofdoxorubicintherapyPharmaciaUpjohnCompanyOctvinorelbineNavelbineNavelbineisindicatedasasingleagentorincombinationwithcisplatinforthefirstlinetreatmentofambulatorypatientswithunreseactable,advancednonsmallcelllungcancer(NSCLC)InpatientswithStageIVNSCLC,NavelbineisindicatedasasingleagentorincombinationwithcisplatinInStageIIINSCLC,NavelbineisindicatedincombinationwithcisplatinGlaxoSmithKlineNovmitomycinCMitozytrextherapyofdisseminatedadenocarcinomaofthestomachorpancreasinprovencombinationswithotherapprovedchemotherapeuticagentsandaspalliativetreatmentwhenothermodalitieshavefailedSupergenNovdocetaxelTaxotereincombinationwithcisplatinforthetreatmentofpatientswithunresectable,locallyadvancedormetastaticnonsmallcelllungcancerwhohavenotpreviouslyreceivedchemotherapyforthisconditionAventisPharmaceuticalNovdocetaxelTaxotere AventisPharmaceuticalNovimatinibmesylateGleevecAccelApprov(clinicalbenefitnotestablished)InitialtreatmentofnewlydiagnosedPhchronicmyelogenousleukemia(CML)NovartisDecletrozoleFemara NovartisJanTositumomabBexxarAccelApprov(clinicalbenefitnotestablished)TreatmentofpatientswithCDpositive,follicular,nonHodgkin'slymphoma,withandwithouttransformation,whosediseaseisrefractorytoRituximabandhasrelapsedfollowingchemotherapyCorixaCorporationJu

用户评价(0)

关闭

新课改视野下建构高中语文教学实验成果报告(32KB)

抱歉,积分不足下载失败,请稍后再试!

提示

试读已结束,如需要继续阅读或者下载,敬请购买!

评分:

/21

意见
反馈

立即扫码关注

爱问共享资料微信公众号

返回
顶部

举报
资料